Global Biosimilar Sales Market Report 2020

A product is termed as biosimilar product, if it is a biological product with similar characteristics as that of a reference biological product, which possesses approval from agencies such as FDA. There would not be any major clinical difference in effectiveness and safety as that of reference product. Biosimilar products are made of complex molecules with high molecular weight produced through genetic engineering in living cells. Biologics drugs are costlier than respective chemical drugs. Biosimilar drugs can save around 30 to 40 % in terms of price relative to the respective biologics drugs. Biosimilars are useful for the treatment of illnesses such as anemia, autoimmune diseases, cancer, diabetes, growth hormone deficiencies, hematological diseases, kidney failure, rheumatoid arthritis and others. For the manufacturing of biosimilars, manufacturers have to develop environments that are ideal for the living cells, which remain sensitive to environmental conditions. Moreover, they need to develop distinctive process to entice the living cells for producing similar outcome to a prevalent biological treatment. The substitution of biological drugs with biosimilar drugs can save lot of money for public health care sector and patients. The regulatory authorities in developed nations are promoting biosimilar products.

Market Analysis and Insights: Global Biosimilar Market
The global Biosimilar market size is projected to reach US$ 14790 million by 2026, from US$ 6919.4 million in 2020, at a CAGR of 13.5% during 2021-2026.

Global Biosimilar Scope and Market Size
The global Biosimilar market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilar market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.

Segment by Type, the Biosimilar market is segmented into
Human Growth Hormones
Monoclonal Antibodies
Insulin
Peptides
Erythropoietin
Others

Segment by Application, the Biosimilar market is segmented into
Oncology
Chronic and Autoimmune Diseases
Growth Hormone Deficiency
Infectious Diseases
Others

The Biosimilar market is analysed and market size information is provided by regions (countries). Segment by Application, the Biosimilar market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape

and Biosimilar Market Share Analysis
Biosimilar market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Biosimilar business, the date to enter into the Biosimilar market, Biosimilar product introduction, recent developments, etc.

The major vendors covered:
Allergan plc
BIOCAD
Biocon
BioXpress Therapeutics
Boehringer Ingelheim
Celltrion
Coherus BioSciences
Dr. Reddy’s Laboratories
Genor BioPharma
Intas Pharmaceuticals Limited
Novartis
Pfizer
Reliance Life Sciences

Frequently Asked Questions